Cargando…
Increase in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI)
Clopidogrel resistance is an important risk factor of ischemic event recurrence after optimal antiplatelet therapy. This study aims to investigate the role of CYP2C19 gene DNA methylation as one of the epigenetic factors for the risk of clopidogrel resistance in STEMI patients undergoing PPCI. ST‐se...
Autores principales: | Sukmawan, Renan, Hoetama, Erick, Suridanda Danny, Siska, Giantini, Astuti, Listiyaningsih, Erlin, Gilang Rejeki, Vidya, Aziz Alkatiri, Amir, Firdaus, Isman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7915409/ https://www.ncbi.nlm.nih.gov/pubmed/33641235 http://dx.doi.org/10.1002/prp2.738 |
Ejemplares similares
-
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention
por: Giantini, Astuti, et al.
Publicado: (2023) -
Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013) -
No-Reflow after PPCI—A Predictor of Short-Term Outcomes in STEMI Patients
por: Pantea-Roșan, Larisa Renata, et al.
Publicado: (2020) -
Combined transepicardial and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction
por: Soetisna, Tri Wisesa, et al.
Publicado: (2020) -
Comparison of Different Risk Scores for Prediction of In-Hospital Mortality in STEMI Patients Treated with PPCI
por: Wang, Chih-Hwa, et al.
Publicado: (2022)